Prima Biomed in trading halt
17 November, 2009 by Tim DeanPrima Biomed shares halted pending announcement of oral vaccine for cervical cancer.
Biotech profile: NemGenix
17 November, 2009 by Tim DeanEarly-stage biotechnology companies were hardest hit by the GFC, but NemGenix has made it through by embracing every form of funding available.
Centre of Kinomics to open 'Pandora's box' of drug development
13 November, 2009 by Tim Dean$1 million Ramaciotti foundation award to create world's first centre to study kinomics.
Australian biotech market watch 11/11/09
11 November, 2009 by Tim DeanBiota Holdings, ChemGenex, pSividia, Patrys, Blackmores
Patrys moves forward with ARC grant
11 November, 2009 by Tim DeanUniversity of Melbourne researchers collaborating with Patrys receive $300K grant for anti-cancer treatment.
Biotech market spotlight: Mesoblast
09 November, 2009 by Tim DeanMesoblast (ASX:MSB) ups and downs after trial successes.
Opinion: Xenotransplantation: medical advance denied
09 November, 2009 by Staff WritersWith New Zealand government recently opening the door to xenotransplantation trials – it is time for the Australian government to reconsider its moratorium.
Biotech profile: Pharmaxis
04 November, 2009 by Tim DeanEven in the world's worst economic downturn since the Great Depression, Sydney-based Pharmaxis (ASX:PXS) managed to grow and open a new headquarters and factory.
Australian biotech market watch 02/11/09
02 November, 2009 by Tim DeanCochlear, CSL, Blackmores, Ansell, Biota, HealthScope
Feature: Regulatory headache for IVDs
02 November, 2009 by Tim DeanThe long delayed regulation of in vitro diagnostics is on its way, possibly as early as this year. Manufacturers should prepare themselves to face the TGA.
Biotech market spotlight: Blackmores
30 October, 2009 by Tim DeanBlackmores (ASX:BKL) shows strong performance, aided by swine flu concerns.
Australian biotech market watch 30/10/09
30 October, 2009 by Tim DeanCochlear, CSL, Sonic Healthcare, Ansell, Blackmores, Greencross, Acrux
Sirtex Medical to open facility in Singapore
27 October, 2009 by Staff Writers$2 million facility to manufacture SIR-Spheres to open within 18 months.
Sirtex Medical: Biotech Market Spotlight
23 October, 2009 by Tim DeanSirtex Medical (ASX:SRX) continues to gain ground on the back of strong profits.
Biotech stocks surge post-GFC
22 October, 2009 by Tim DeanAustralian life science sector showing strong sustained growth, according to PwC.
